Stock Track | Alvotech Soars 6.13% in Pre-Market After Clearing Key FDA Inspection

Stock Track05-11

Alvotech's stock surged 6.13% in pre-market trading on Monday, following a significant regulatory update from the biosimilar developer.

The price movement comes after the company announced that the U.S. Food and Drug Administration has completed a routine cGMP surveillance inspection of its manufacturing facility in Reykjavik, Iceland. The FDA concluded the inspection and issued a Form 483, but Alvotech stated that the observations can be addressed quickly and do not raise any substantial issues with the site or its operations.

This positive inspection outcome positions Alvotech to resubmit its relevant Biologics License Applications (BLAs) in the current quarter. The company continues to expect FDA approval for these biosimilar candidates during 2026, marking a crucial step forward for its product pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment